Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118456 · ClinicalTrials.gov registry record · Phase 1
Study of Oral AEE788 in Adults With Advanced Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 189
- Enrollment target
NCT00118456: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT00118456 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 189 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (215% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00118456, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 189 participants
- Enrollment target
Study Summary
AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, pharmacokinetic (PK)/pharmacodynamic (PD) profiles and clinical activity of AEE788 in advanced cancers.
Interventions
- DRUG AEE788
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2003-07 |
| Phase | Phase 1 |
What the finished NCT00118456 record still lists
NCT00118456 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (215% higher).
The record links to 0 conditions, and to 1 intervention - of which AEE788 is the first listed.
NCT00118456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00118456 about?
NCT00118456 is a clinical study titled "Study of Oral AEE788 in Adults With Advanced Cancer". AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, pharma...
What is the current status of trial NCT00118456?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 189 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00118456?
The interventions under investigation include: AEE788 (DRUG).
Who is sponsoring clinical trial NCT00118456?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00118456's enrollment target sits among peer trials
189 288th of 2000 higher than 1,712 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia